Altered endocannabinoid system gene expression in inflammatory bowel disease mucosa: New perspectives in inflammatory bowel disease management

Table 1 Sociodemographic and clinical data of the individuals involved in the study

Feature	CTRL (n = 17)	IBD (n = 30)	UC (n = 17)	CD (n = 13)	P value
Age	48.12 ± 17.46	49.60 ± 14.53	48.82 ± 11.89	49.31 ± 17.94	P = 0.756 (CTRL vs IBD); P = 0.741 (CTRL vs UC); P = 0.829 (CTRL vs CD)
Sex M, F	52.9% F; 47.1% M	20% F; 80% M	11.76% F; 88.24% M	30.77% F; 69.23% M	P = 0.020; χ2 = 5.419 (CTRL vs IBD); P = 0.026; χ2 = 6.585 (CTRL vs UC); P = 0.283; χ2 = 1.475 (CTRL vs CD)
Disease status		23.3% remission; 76.7% active	23.5% remission; 76.5% active	23.1% remission; 76.9% active	P = 0.999; χ2 = 0.977 (UC vs CD)
Age at onset (mean ± SD)		44.3 ± 14.55	48.82 ± 11.72	42.31 ± 17.93	P = 0.522 (UC vs CD)
Therapeutic regimen		23.3% drug free; 56.7% 5-ASA; 6.7% AZA; 13.3% biological treatment	29.4% drug free; 64.7% 5-ASA; 5.9% AZA	15.4% drug free; 46.2% 5-ASA; 7.7% AZA; 30.7% biological treatment	P = 0.096; χ2 = 6.336 (UC vs CD)
Extension (UC) and Location (CD)- Montreal			5.9% E1; 35.3% E2; 8.8% E3	15.4% L1; 23.1% L2; 61.5% L3
Behaviour- montreal				46.2% B1; 38.4% B2; 15.4% B3

IBD: Inflammatory bowel disease; UC: Ulcerative colitis; CD: Crohn’s disease; CTRL: Non-inflammatory bowel disease controls; M: Male; F: Female; 5-ASA: Aminosalicylates ; AZA: Azathioprine; E1: Proctitis; E2: Left-sided colitis; E3: Pancolitis; L1: Lerminal ileal; L2: Colon; L3: Leocolon; B1: Non-stricturing, non-penetrating; B2: Stricturing; B3: Penetrating.